Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fresenius kabi ab - kaliumjodid; kopparkloriddihydrat; mangankloridtetrahydrat; natriumselenit, vattenfri; zinkklorid - koncentrat till infusionsvätska, lösning - zinkklorid 1042 mikrog aktiv substans; natriumselenit, vattenfri 15,33 mikrog aktiv substans; kaliumjodid 2,567 mikrog aktiv substans; kopparkloriddihydrat 107,4 mikrog aktiv substans; mangankloridtetrahydrat 3,6 mikrog aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiska medel - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibakteriella medel för systemiskt bruk, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. hänsyn bör tas till officiella riktlinjer för lämplig användning av antibakteriella medel.

Europeiska unionen - svenska - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glykogenlagringssjukdomstyp ii - andra matsmältningsorgan och ämnesomsättning produkter, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mundipharma ab - hydromorfonhydroklorid - kapsel, hård - 1,3 mg - hydromorfonhydroklorid 1,3 mg aktiv substans; natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne; laktos (vattenfri) hjälpämne - hydromorfon

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mundipharma ab - hydromorfonhydroklorid - injektions-/infusionsvätska, lösning - 10 mg/ml - hydromorfonhydroklorid 10 mg aktiv substans - hydromorfon

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mundipharma ab - hydromorfonhydroklorid - depotkapsel, hård - 16 mg - hydromorfonhydroklorid 16 mg aktiv substans; natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne - hydromorfon

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mundipharma ab - hydromorfonhydroklorid - injektions-/infusionsvätska, lösning - 2 mg/ml - hydromorfonhydroklorid 2 mg aktiv substans - hydromorfon

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mundipharma ab - hydromorfonhydroklorid - kapsel, hård - 2,6 mg - hydromorfonhydroklorid 2,6 mg aktiv substans; laktos (vattenfri) hjälpämne; natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne - hydromorfon

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mundipharma ab - hydromorfonhydroklorid - injektions-/infusionsvätska, lösning - 20 mg/ml - hydromorfonhydroklorid 20 mg aktiv substans - hydromorfon